Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2026)

Neurocrine Biosciences' Cost of Revenue history runs 10 years deep, the most recent figure standing at $13.8 million for Q1 2026.

• Quarterly Cost of Revenue rose 50.0% year-over-year to $13.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.7 million (up 58.82% YoY) and the FY2025 annual result came in at $52.1 million, up 53.24% from the prior year.
• Cost of Revenue was $13.8 million for Q1 2026 at Neurocrine Biosciences, down from $17.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $17.6 million in Q4 2025 and bottomed at $4.6 million in Q1 2022.
• A 5-year average of $9.6 million and a median of $9.2 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2023 — Cost of Revenue soared 139.58% — and 2024, when it retreated 28.57%.
• Neurocrine Biosciences' Cost of Revenue stood at $7.7 million in 2022, then gained by 10.39% to $8.5 million in 2023, then advanced by 9.41% to $9.3 million in 2024, then soared by 89.25% to $17.6 million in 2025, then retreated by 21.59% to $13.8 million in 2026.
• Business Quant data shows NBIX's Cost of Revenue at $13.8 million in Q1 2026, $17.6 million in Q4 2025, and $14.0 million in Q3 2025.